Q-omics provides the consensus-scored TOB1 profile across patient tissues and cancer cell-line models. TOB1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TOB1 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, TOB1 RNA expression shows 20,172 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where TOB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TOB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TOB1 survival associations across molecular data types. TOB1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TOB1 RNA expression–survival associations across cancer types. High TOB1 expression shows unfavorable associations in UVM, PAAD, LGG and ACC, but favorable associations in KIRC and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for TOB1 RNA expression.
This table summarizes TOB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TOB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TOB1 shows lower tumor expression in THCA, KICH, KIRC and HNSC and higher tumor expression in BRCA and PAAD. The THCA box plot shows higher TOB1 RNA expression in normal versus tumor tissue (log2 FC = −2.041, t-test p < 0.001).
This table shows molecular features associated with TOB1 in patient tissues and cancer cell lines. In patient samples, TOB1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TOB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
